Compare Bill.com Holdings Inc (BILL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Novo Nordisk A/S — how do they compare? Bill.com Holdings Inc trades at $48.37 (market cap $4.93B), while Novo Nordisk A/S trades at $46.29 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 42.2× Bill.com Holdings Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | NVO | |
|---|---|---|
Market Cap | $4.93B | $207.85B |
Sector | Technology | Health |
52-Week High | $56.32 | $63.98 |
52-Week Low | $31.96 | $35.29 |
Enterprise Value | $4.64B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $48.37, down 1.81% today, with a bullish technical signal and strong analyst support (56% buy ratings). The company shows improving fundamentals with revenue growth to $1.46B in 2025 and three consecutive quarterly EPS beats, though profitability remains thin with a net margin of 0.01%. Recent news highlights AI-driven strategy and operational efficiency gains.
Outlook is cautiously optimistic given earnings momentum and institutional accumulation, but high valuation (P/E 213.91) and negative cash flow from investing pose risks. Upside to consensus price target $45.67 appears limited at current levels, requiring sustained execution for further gains.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
